Jung Choi has bought stock on 2 days since Aug 2015

Jung E. Choi is an accomplished biotechnology executive serving as an independent Director on the Board of Directors of Annexon, Inc. (NASDAQ: ANNX), a clinical-stage biopharmaceutical company developing therapies for complement-mediated diseases.( On December 1, 2025, she purchased 33,000 shares at $4.19 per share, signaling confidence in the company's prospects amid market volatility.(

Choi has a distinguished career in biotech business development, having led over 50 transactions exceeding $13 billion in value. She joined Global Blood Therapeutics (GBT) in 2015 as Chief Business and Strategy Officer, overseeing business development, corporate strategy, patient advocacy, and government affairs. Previously, she was Senior Vice President of Corporate Development at InterMune (acquired by Roche) and Chimerix, and held leadership roles at Gilead Sciences, including building the corporate development group and launching Hepsera for chronic hepatitis B. Earlier positions include Vice President at Bay City Capital and Engagement Manager at McKinsey & Company. She holds a B.A. in human biology and an M.B.A. from Stanford University, and is an Aspen Health Innovators Fellow.(

Written by Perplexity from public sources.